A new genetic test could save more women with breast cancer from having to go through chemotherapy.
The EndoPredict test, which takes just a few days, can accurately predict if a woman’s cancer is likely to spread around the body.
Doctors would be able to see the genetic make-up of a tumour giving them a clearer indication of how the cancer would develop over the next 10 years.
What makes EndoPredict particularly advantageous over the current service offered on the NHS is its speed.
The current test Oncotype DX takes 14 days and has to be sent over the US for analysis. EndoPredict on the other hand takes just a few days and can be done here in the UK.
This information can be used to inform personalised treatment decisions by identifying which patients would be most likely to benefit from treatment with chemotherapy after surgery and those who won’t need it, thereby avoiding unnecessary side-effects.
Woman’s Breast Selfie Shows Little-Known Symptom Of Cancer - Can You Spot It?
Breast Cancer Tumours ‘Disappeared Or Shrunk Significantly’ In 11 Days With New Drug Treatment
Six Things You Didn’t Know About Male Breast Cancer That You Definitely Should
Both tests are for women with oestrogen receptor positive, HER2 negative (ER+/HER2-) disease, which accounts for around two-thirds of all breast cancers.
More than 33,000 women are diagnosed with ER+/HER2- breast cancer each year in the UK.
By identifying those at low risk of their disease spreading, women who would see little benefit from chemotherapy could be spared its gruelling side-effects.
The study - led by researchers at the Institute of Cancer Research in London and the Royal Marsden NHS Foundation Trust in collaboration with Queen Mary University of London, and published on Monday in the Journal of the National Cancer Institute - compared the performance of EndoPredict and Oncotype DX.
A woman’s risk of her cancer spreading is calculated using the results from the genetic test combined with the size of her tumour and whether disease has spread to the lymph nodes.
Women are classed as low risk if they have less than a 10% decade-long risk of their cancer spreading.
In the study, just 5.8% of all patients identified as low risk by EndoPredict went on to see their cancer spread over a decade compared with 10.1% of patients identified as low risk by Oncotype DX.
Study lead author Dr Richard Buus, from the Institute of Cancer Research, London, said: “This study showed that a new test is more accurate than the current NHS standard test at detecting women at lowest risk of their breast cancer spreading to other parts of the body in the long-term.
“It could help improve treatment for a large number of women with breast cancer by allowing doctors to better predict which women are least likely to go on to develop secondary cancer – and could therefore be spared from undergoing the chemotherapy often offered early on in treatment to reduce that risk.”
Baroness Delyth Morgan, chief executive of Breast Cancer Now, said: “This important study demonstrates the exciting potential of EndoPredict to identify breast cancer patients that will benefit little from chemotherapy. This test could give patients and their doctors invaluable reassurance that they may safely be spared chemotherapy’s gruelling side-effects.
“Oncotype DX remains a valuable tool for both clinicians and patients. But we need to see the best and most cost-effective technologies made routinely available on the NHS, and this research suggests EndoPredict could be another step forward.
“Based on this strong evidence, we would encourage the National Institute for Health and Care Excellence (Nice) to consider this technology for routine use on the NHS.”